{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:06:47Z","timestamp":1781550407949,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["NIHR201124"],"award-info":[{"award-number":["NIHR201124"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obstructive sleep apnoea (OSA) involves repeated breathing pauses during sleep due to upper airway obstruction. It causes excessive daytime sleepiness and has other health impacts. Continuous positive airway pressure (CPAP) therapy is effective first line treatment for moderate to severe OSA. Unfortunately, many patients have difficulty tolerating CPAP and pressure intolerance is probably an important contributing factor. Mandibular advancement devices (MAD) are an alternative to CPAP. They are worn in the mouth during sleep to reduce airway obstruction. There is some evidence that, when used in combination with CPAP, MADs improve airway anatomy enough to reduce the CPAP pressure required to treat OSA and that this combination therapy could improve CPAP adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive patients starting on CPAP for moderate to severe OSA will be recruited at a regional NHS sleep service. Patients with high CPAP pressure requirements after initial titration, who satisfy all entry criteria and consent to participate, will undertake a 2-arm randomised crossover trial. The arms will be (i) standalone CPAP and (ii) CPAP\u2009+\u2009MAD therapy. Each arm will last 12\u00a0weeks, including 2\u00a0weeks acclimatisation. CPAP machines will be auto-titrating and with facility for data download, so the impact of MAD on CPAP pressure requirements and CPAP adherence can be easily measured. The primary outcome will be CPAP adherence. Secondary outcomes will include measures of OSA severity, patient-reported outcome measures including subjective daytime sleepiness, quality of life, and treatment preference at the trial exit and health service use. Cost-effectiveness analyses will be undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>If the intervention is shown to be effective and cost-effective in improving adherence in this standard CPAP-eligible OSA patient population it would be relatively straightforward to introduce into existing OSA treatment pathways, within the wider NHS and more widely. Both MAD and CPAP are already used by sleep services so their combination would require only minor adjustments to existing clinical pathways. It would be straightforward to disseminate the results of the study through regional, national, and international respiratory meetings. The health economics analysis would provide cost-effectiveness data to inform service planning and clinical guidelines through policy briefing papers, including those by NICE and SIGN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      PAPMAT was registered with ISRCTN prior to recruitment beginning (ISRCTN Registry 2021):\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN33966032\" ext-link-type=\"uri\">https:\/\/www.isrctn.com\/ISRCTN33966032<\/jats:ext-link>\n                      . Registered on 17th November 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07484-w","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T09:02:37Z","timestamp":1690189357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Continuous Positive Airway Pressure plus Mandibular Advancement Therapy (PAPMAT): study protocol for an adaptive randomised crossover trial comparing the benefits and costs of combining two established treatments for obstructive sleep apnoea"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-348X","authenticated-orcid":false,"given":"Martin","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Oscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Stoneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Fox-Rushby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Da","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Claydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Keat","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Quinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"7484_CR1","doi-asserted-by":"publisher","unstructured":"ISRCTN Registry. ISRCTN - ISRCTN33966032: Mandibular advancement device plus continuous positive airway pressure: does combining two established treatments for obstructive sleep apnoea give added benefits? 2021. Available from: \nhttps:\/\/doi.org\/10.1186\/ISRCTN33966032. Cited 2022 11 10.","DOI":"10.1186\/ISRCTN33966032"},{"key":"7484_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1389-9457(01)00072-7","volume":"2","author":"CA Moyer","year":"2001","unstructured":"Moyer CA, Sonnad SS, Garetz SL, Helman JI, Chervin RD. Quality of life in obstructive sleep apnea: a systematic review of the literature. Sleep Med. 2001;2:477\u201391.","journal-title":"Sleep Med"},{"key":"7484_CR3","first-page":"ii45","volume":"56","author":"JR Stradling","year":"2001","unstructured":"Stradling JR, Pepperell JCT, Davies RJO. Sleep apnoea and hypertension: proof at last? Thorax. 2001;56:ii45\u20139.","journal-title":"Thorax"},{"key":"7484_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.atherosclerosis.2013.04.026","volume":"229","author":"JY Dong","year":"2013","unstructured":"Dong JY, Zhang YH, Qin LQ. Obstructive sleep apnea and cardiovascular risk: Meta-analysis of prospective cohort studies. Atherosclerosis. 2013;229:489\u201395.","journal-title":"Atherosclerosis"},{"key":"7484_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18670","volume":"18","author":"L Sharples","year":"2014","unstructured":"Sharples L, Glover M, Clutterbuck-James A, Bennett M, Jordan J, Chadwick R, et al. Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea\u2013hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure. Health Technol Assess. 2014;18:1\u2013296.","journal-title":"Health Technol Assess"},{"key":"7484_CR6","unstructured":"Health NI, Excellence C. Continuous positive airway pressure for the treatment of obstructive sleep apnoea\/hypopnoea syndrome. NICE technology appraisal guidance 139. 2008. https:\/\/www.nice.org.uk\/guidance\/ta139."},{"key":"7484_CR7","doi-asserted-by":"publisher","unstructured":"Smith I, Lasserson TJ. Pressure modification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009;(4):CD003531. https:\/\/doi.org\/10.1002\/14651858.CD003531.","DOI":"10.1002\/14651858.CD003531"},{"key":"7484_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/thoraxjnl-2014-205464","volume":"69","author":"TG Quinnell","year":"2014","unstructured":"Quinnell TG, Bennett M, Jordan J, Clutterbuck-James AL, Davies MG, Smith IE, et al. A crossover randomised controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea (TOMADO). Thorax. 2014;69:938\u201345.","journal-title":"Thorax"},{"key":"7484_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.wjorl.2015.08.001","volume":"1","author":"M Knauert","year":"2015","unstructured":"Knauert M, Naik S, Gillespie MB, Kryger M. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World J Otorhinolaryngol Head Neck Surg. 2015;1:17\u201327.","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"7484_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1515\/reveh-2018-0068","volume":"34","author":"NE Morsy","year":"2019","unstructured":"Morsy NE, Farrag NS, Zaki NFW, Badawy AY, Abdelhafez SA, El-Gilany AH, et al. Obstructive sleep apnea: personal, societal, public health, and legal implications. Rev Environ Health. 2019;34:153\u201369.","journal-title":"Rev Environ Health"},{"key":"7484_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1532-5415.2007.01544.x","volume":"56","author":"A Tarasiuk","year":"2008","unstructured":"Tarasiuk A, Greenberg-Dotan S, Simon-Tuval T, Oksenberg A, Reuveni H. The effect of obstructive sleep apnea on morbidity and health care utilization of middle-aged and older adults. J Am Geriatr Soc. 2008;56:247\u201354.","journal-title":"J Am Geriatr Soc"},{"key":"7484_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/sleep\/29.10.1307","volume":"29","author":"K Banno","year":"2006","unstructured":"Banno K, Manfreda J, Walld R, Delaive K, Kryger MH. Healthcare utilization in women with obstructive sleep apnea syndrome 2 years after diagnosis and treatment. Sleep. 2006;29:1307\u201311.","journal-title":"Sleep"},{"key":"7484_CR13","doi-asserted-by":"publisher","first-page":"e0187032","DOI":"10.1371\/journal.pone.0187032","volume":"12","author":"HW Liu","year":"2017","unstructured":"Liu HW, Chen YJ, Lai YC, Huang CY, Huang YL, Lin MT, et al. Combining MAD and CPAP as an effective strategy for treating patients with severe sleep apnea intolerant to high-pressure PAP and unresponsive to MAD. PLoS One. 2017;12:e0187032.","journal-title":"PLoS One"},{"key":"7484_CR14","doi-asserted-by":"crossref","unstructured":"McDaid C, Griffin S, Weatherly H, Dur\u00e9e K, Burgt M, Hout S, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea\u2013hypopnoea syndrome: a systematic review and economic analysis. Health Technol Assess. 2009;13:53\u201387.","DOI":"10.3310\/hta13040"},{"key":"7484_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/thx.2007.086454","volume":"63","author":"JF Guest","year":"2008","unstructured":"Guest JF, Helter MT, Morga A, Stradling JR. Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnoea\/hypopnoea syndrome in the UK. Thorax. 2008;63:860\u20135.","journal-title":"Thorax"},{"key":"7484_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/thorax.57.1.93","volume":"57","author":"NJ Douglas","year":"2002","unstructured":"Douglas NJ. Treating sleep apnoea is cost effective. Thorax. 2002;57:93\u201393.","journal-title":"Thorax"},{"key":"7484_CR17","unstructured":"Juan Carlos Rej\u00f3n-Parrilla MGaJS. Obstructive sleep apnoea health economics report. Consulting Report. British Lung Foundation; https:\/\/snorer.com\/wp-content\/uploads\/2015\/05\/OHE-OSA-health-economics-report---FINAL---v2.pdf."},{"key":"7484_CR18","first-page":"77","volume":"39","author":"NM Siyasinghe","year":"2011","unstructured":"Siyasinghe NM, Sooriyarachchi MR. Guidelines for calculating sample size in 2x2 crossover trials\u202f: a simulation study. J Natl Sci Found. 2011;39:77.","journal-title":"J Natl Sci Found"},{"key":"7484_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287\u201391.","journal-title":"Pharm Stat"},{"key":"7484_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/bimj.4710380806","volume":"38","author":"M Kieser","year":"1996","unstructured":"Kieser M, Wassmer G. On the Use of the Upper Confidence Limit for the Variance from a Pilot Sample for Sample Size Determination. Biom J. 1996;38:941\u20139.","journal-title":"Biom J"},{"key":"7484_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","volume":"65","author":"J Sim","year":"2012","unstructured":"Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65:301\u20138.","journal-title":"J Clin Epidemiol"},{"key":"7484_CR22","doi-asserted-by":"crossref","unstructured":"Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014;15:1.","DOI":"10.1186\/1745-6215-15-264"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07484-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07484-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07484-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:23:55Z","timestamp":1762417435000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07484-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7484"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07484-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2786783\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before the start of the study, or implementation of any amendment, approval of the trial protocol, protocol amendments, informed consent forms and other relevant documents will be obtained from the Regional Ethics Committee (REC) and Health Research Authority (HRA). All correspondence with the REC and RfPB will be retained in the Trial Master File (Sponsor File\/Investigator Site File).Annual reports will be submitted to the REC in accordance with national requirements. It is the Chief Investigator\u2019s responsibility to produce the annual reports as required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"A model consent form can be provided on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"474"}}